--- title: "ADMA Biologics (ADMA) stock: news and investor profile" url: "https://aibio.space/companies/adma-biologics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ADMA Biologics Inc (NASDAQ: ADMA), United States. The directory classifies it as Biotechnology." --- ADMA ADMA Biologics Inc NASDAQ · United States # ADMA Biologics (ADMA) news Debt Financing · 2025-08-06 ## [ADMA Biologics enters $300 million credit agreement led by J.P. Morgan, repays Ares facility](https://aibio.space/news/adma-biologics-enters-300-million-credit-agreement-led-j-p-morgan/) The agreement provides a $75 million term loan and a $225 million revolving credit facility, both maturing August 5, 2028. ADMA used the proceeds to pay off its earlier facility with Ares Capital Corporation. ## Latest ADMA Biologics news 1. 2025-03-03 Distress [ADMA Biologics files NT 10-K, says 2024 annual report will be late](https://aibio.space/news/adma-biologics-files-nt-10-k-says-2024-annual-report-will-late/) ADMA Biologics said on March 3, 2025 that KPMG LLP has not finished its audit of 2024 and expects to file the annual report by March 18, 2025. The notice attaches unaudited 2024 net income of 197,673 thousand dollars, against a 2023 net loss of 28,239 thousand dollars. ## ADMA Biologics at a glance - **Ticker**: ADMA - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $136.0 million ### Related companies - [Lyell Immunopharma](https://aibio.space/companies/lyell-immunopharma/) NASDAQ: LYEL - [NovelStem International](https://aibio.space/companies/novelstem-international/) OTC: NSTM - [AVVAA World Health Care Products](https://aibio.space/companies/avvaa-world-health-care-products/) OTC: AVVH - [Lakewood-Amedex Biotherapeutics](https://aibio.space/companies/lakewood-amedex-biotherapeutics/) NASDAQ: LABT - [NeoImmuneTech](https://aibio.space/companies/neoimmunetech/) KRX: 950220 - [Invivyd](https://aibio.space/companies/invivyd/) NASDAQ: IVVD - [Statera Biopharma](https://aibio.space/companies/statera-biopharma/) OTC: STAB - [LianBio](https://aibio.space/companies/lianbio/) OTC: LIANY ### Also on NASDAQ - [Gyre Therapeutics](https://aibio.space/companies/gyre-therapeutics/) GYRE - [LeonaBio](https://aibio.space/companies/leonabio/) LONA - [Brainsway](https://aibio.space/companies/brainsway/) BWAY - [Liminatus Pharma](https://aibio.space/companies/liminatus-pharma/) LIMN - [Estrella Immunopharma](https://aibio.space/companies/estrella-immunopharma/) ESLA - [NEOGENOMICS INC](https://aibio.space/companies/neogenomics/) NEO ## What ADMA Biologics does ADMA Biologics is a U.S.-based commercial biopharmaceutical company that manufactures, markets and develops specialty plasma-derived biologics for immunodeficient patients and others at risk for certain infectious diseases. It has three FDA-approved products, all marketed: ASCENIV and BIVIGAM, both intravenous immune globulin products for primary immunodeficiency, and Nabi-HB, a hepatitis B immune globulin for acute exposure to blood containing HBsAg. The company manufactures these products at its FDA-licensed plasma fractionation facility in Boca Raton, Florida. Its ADMA BioCenters subsidiary operates source plasma collection centers in the U.S., which supply plasma for manufacturing and sales to third parties. The pipeline includes SG-001, an S. pneumoniae hyperimmune globulin, for which a pilot-scale batch has been produced and animal studies are under way, with a pre-IND submission anticipated in fiscal year 2026. An FDA-approved yield enhancement process for ASCENIV and BIVIGAM is expected to increase production yields by 20% or more from the same starting source plasma volume. In December 2025 the company agreed to divest three plasma collection centers for $12.0 million. | Product or program | What it is | Stage | |---|---|---| | ASCENIV | Intravenous immune globulin for primary humoral immunodeficiency in adults and adolescents | marketed | | BIVIGAM | Intravenous immune globulin for primary immunodeficiency in adults and pediatric patients | marketed | | Nabi-HB | Hepatitis B immune globulin for acute exposure to blood containing HBsAg | marketed | | SG-001 | S. pneumoniae hyperimmune globulin | animal studies; pre-IND submission anticipated in fiscal year 2026 | Summarised from the company's [10-K filed Feb 25, 2026](https://www.sec.gov/Archives/edgar/data/1368514/000114036126006815/ef20059416_10-k.htm). ## ADMA Biologics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$4.8 million](https://www.sec.gov/Archives/edgar/data/1368514/000114036126006815/) | [$1.8 million](https://www.sec.gov/Archives/edgar/data/1368514/000114036126006815/) | | Net income (loss) | [$146.9 million](https://www.sec.gov/Archives/edgar/data/1368514/000114036126006815/) | [$197.7 million](https://www.sec.gov/Archives/edgar/data/1368514/000114036126006815/) | | Cash from operations | [$50.4 million](https://www.sec.gov/Archives/edgar/data/1368514/000114036126006815/) | [$118.7 million](https://www.sec.gov/Archives/edgar/data/1368514/000114036126006815/) | | Cash and equivalents | [$87.6 million](https://www.sec.gov/Archives/edgar/data/1368514/000114036126031445/) | [$103.1 million](https://www.sec.gov/Archives/edgar/data/1368514/000114036126006815/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $136.0 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about ADMA Biologics What is the ticker symbol of ADMA Biologics? ADMA Biologics Inc trades under the ticker ADMA on NASDAQ. Where is ADMA Biologics listed? ADMA Biologics Inc is listed on NASDAQ. What is the SEC CIK of ADMA Biologics? The SEC Central Index Key (CIK) for ADMA Biologics Inc is 1368514. Its filings are on SEC EDGAR. How many shares does ADMA Biologics have outstanding? 223,984,680 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-05. Which country or territory is ADMA Biologics listed under? Our directory records ADMA Biologics Inc under United States. What does ADMA Biologics do? Our directory classifies ADMA Biologics Inc as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of ADMA Biologics? The ISIN recorded for ADMA Biologics Inc is US0008991046. Does aibio.space cover ADMA Biologics? aibio.space lists ADMA Biologics Inc among 2,820 public biotech companies and publishes its news here as stories appear. Where is ADMA Biologics incorporated? SEC records list its state or country of incorporation as DE. What does ADMA Biologics develop? ADMA Biologics is a U.S.-based commercial biopharmaceutical company that manufactures, markets and develops specialty plasma-derived biologics for immunodeficient patients and others at risk for certain infectious diseases. It has three FDA-approved products, all marketed: ASCENIV and BIVIGAM, both intravenous immune globulin products for primary immunodeficiency, and Nabi-HB, a hepatitis B immune globulin for acute exposure to blood containing HBsAg. What is ASCENIV from ADMA Biologics? ASCENIV: Intravenous immune globulin for primary humoral immunodeficiency in adults and adolescents Stage: marketed. What is BIVIGAM from ADMA Biologics? BIVIGAM: Intravenous immune globulin for primary immunodeficiency in adults and pediatric patients Stage: marketed. Is ADMA Biologics profitable? ADMA Biologics Inc reported net income of $146.9 million for the fiscal year ended Dec 31, 2025, and generated $50.4 million of cash from operations, per its annual report to the SEC. How much does ADMA Biologics spend on research and development? $4.8 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does ADMA Biologics have? $136.0 million in cash at Jun 30, 2026, per its 10-Q. ## Investor discussion: ADMA Biologics Members talk about ADMA Biologics (ADMA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at ADMA Biologics, newest first. Each line links the filing it comes from. 1. 2026-08-05 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1368514/000114036126031445/ef20075111_10q.htm) 2. 2025-08-06 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02,2.02,2.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1368514/000114036125029143/ef20053140_ex99-1.htm) 3. 2025-03-03 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1368514/000114036125006796/ef20044769-nt10-k.htm) 4. 2024-10-31 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1368514/000114036124044808/ef20037117_8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ADMA on TradingView](https://www.tradingview.com/symbols/NASDAQ-ADMA/). ## SEC filings and registration - **SEC name**: Adma Biologics, Inc. - **CIK**: 1368514 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: ADMA (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: C/O ADMA BIOLOGICS, INC., RAMSEY, NJ, 07446 - **Phone**: (201) 478-5552 - **Shares outstanding**: 223,984,680 as of 2026-07-31 (10-Q filed 2026-08-05) - **Former names**: R&R ACQUISITION VI, INC ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1368514/000114036126031445/ef20075111_10q.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1368514/000114036126031423/ef20079311_8k.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1368514/000114036126023705/ef20075432_8k.htm) filed 2026-06-02 - [10-Q](https://www.sec.gov/Archives/edgar/data/1368514/000114036126019336/ef20070429_10q.htm) filed 2026-05-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1368514/000114036126019295/ef20072554_8k.htm) filed 2026-05-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1368514/000114036126018667/ef20072196_8k.htm) filed 2026-05-04 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1368514/000114036126014799/ny20064057x1_def14a.htm) filed 2026-04-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1368514/000114036126011569/ef20069109_8k.htm) filed 2026-03-27 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001368514), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details ADMA Biologics Inc is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ADMA, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: ADMA Biologics Inc - **Ticker**: ADMA - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US0008991046 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ADMA/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/adma-biologics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "ADMA Biologics (ADMA) stock: news and investor profile", 2026-10-31, https://aibio.space/companies/adma-biologics/